Counting the days till Zyprexa's patent runs out

The Zyprexa countdown nears its end. As the Indianapolis Star reports, there are only 21 days remaining on the blockbuster antipsychotic's patent, meaning Eli Lilly will soon face copycat rivals to its biggest-selling medication ever. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.